AAV-mediated delivery of Abs against targets such as the microtubule associated protein ‘tau’ and vascular endothelial growth factor A (VEGF-A) for the treatment of Alzheimer’s disease (AD) and age-related macular degeneration (AMD), respectively, is being evaluated in preclinical and clinical settings (127, 204). The gene discussed is VEGFA; the disease is Alzheimer disease.